Erin Taylor, a disability advocate and botany enthusiast with ALS, used the technology to introduce herself and then welcome ...

Thompson, who has spent the latter part of his coaching career while suffering from ALS, is much more than a fine football ...

In a post on X.com, Neuralink said it had been granted regulatory approval for "a new feasibility trial to extend BCI control ...

Could Neuralink's brain implant be used to control a robotic arm? Neuralink is therefore launching a new feasibility trial, aimed at extending control of the brain-computer interface using the N1 ...

We recently published a list of 10 Cheapest Stocks to Buy On Robinhood. In this article, we are going to take a look at where ...

WARREN, NJ, USA I6, 2024 I PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the global Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease ...

LYON, France I6, 2024 I MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of ...

Study failed to meet primary and secondary efficacy endpoints - WARREN, N.J., Nov. 26, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced ...

A team at the Montreal Neurological Institute and Hospital – the Neuro – has been helping patients suffering from terminal neurological diseases. The Susan Cameron Cook Neuro-Palliative Care Program ...

A biotech start-up that has shown the ability to pause and in some cases reverse neurodegenerative diseases in mice has ...

Sydney, Australia, 28 November 2024 – Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, has completed one of the largest Series A ...

Sydney-based biotechnology company Celosia Therapeutics has secured $16.75 million in Series A funding to advance its ...